MedPath

Growth Factor Enhanced Matrix With Subepithelial Connective Tissue Graft or Collagen Membrane in Treatment of Gingival Recession

Phase 4
Completed
Conditions
GINGIVAL RECESSION
Interventions
Procedure: GROUP II
Procedure: GROUPI
Registration Number
NCT05782751
Lead Sponsor
Tanta University
Brief Summary

The study aimed to compare, the effectiveness of Growth Factor Enhanced Matrix (GEM 21s) ® combined either with free connective tissue graft or collagen membrane in the treatment of Miller class II gingival recession.

Detailed Description

Materials and Methods: Twenty sites in 10 patients, with class II Miller gingival recession were allocated randomly to be treated by (GEM 21s) ® with free connective tissue graft (groupI) or GEM 21s with collagen membrane (groupII). Plaque index, bleeding on probing, recession width, recession depth, height of keratinized tissue and digital measurements were recorded at baseline, 1, 3 and 6-months'. Probing pocket depth, clinical attachment level, gingival thickness and Radiographic parameters were recorded at baseline and 6 months'. Root coverage percentage were recorded 6 months postoperative and wound healing index were recorded at 1,3 and 6-months' post-operative .

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
10
Inclusion Criteria
  • lack of any related medical issues that contraindicate periodontal surgery,
  • optimum adherence as confirmed by a positive attitude towards oral hygiene, and successfully showing up for treatment appointments.
  • No history of any medications in the previous six months that may interfere with periodontal surgery Gingival thickness for the selected sites should be > 1mm (as measured 2mm apical to gingival margin),
  • Clinical attachment level ≥ 4mm measured from cemento-enamel junction till the deepest probing depth.
Exclusion Criteria
  • the presence of class V caries or restoration in the site to be treated,
  • previous mucogingival surgery at the selected site.
  • Teeth that are tilted, rotated, or have any occlusal abnormalities.
  • Smokers and pregnant patients were excluded from the participation.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
(groupII)GROUP II10 recession sites GEM 21s with collagen membrane
(groupI)GROUPI10 recession sites treated by (GEM 21s) ® with free connective tissue graft
Primary Outcome Measures
NameTimeMethod
Gingival thickness (Gingival biotype)up to 6 months

measured at mid-buccal area 2 mm apical to the free gingival margin measured at baseline, and 6 months postoperatively

Recession widthup to 6 months

the distance between the mesial and distal papillae along the CEJ measured at baseline , 1, 3, and 6 months

radiographic measurements of facial bone level, thickness and densityup to 6 months

from cone beam CT radiography measured at baseline, and 6 months postoperative

Percentage of root coverageup to 6 months

according to the following formula: (RD at baseline - RD at 6 months) / RD at baseline)x100 was calculated after 6 months

recession depthup to 6 months

The distance between the CEJ and the gingival margin at the midbuccal aspect of the involved tooth measured at baseline , 1, 3, and 6 months

Height of keratinized tissueup to 6 months

distance from the most apical point of the free gingival margin to the mucogingival junction mid-facially measured at baseline , 1, 3, and 6 months

Secondary Outcome Measures
NameTimeMethod
probing pocket depthup to 6 months

measured from gingival margin to the bottom of the pocket measured at baseline, 3, and 6 months

healing indexup to 6 months

recorded at 1, 3 and 6 months postoperatively (Score 1: uneventful healing while score 3: poor wound healing

Digital measurementsup to 6 months

all recession areas were photographed The photos were taken by a digital camera at a fixed resolution (mega pixel) taken at baseline, 1,3,and 6 months postoperative

clinical attachment levelup to 6 months

measured from CEJ to the bottom of the pocket measured at baseline, 3, and 6 months

Trial Locations

Locations (2)

Malak Yousef Mohamed Shoukheba

🇪🇬

Tanta, Egypt

Malak Mohamed Shoukheba

🇪🇬

Tanta, Egypt

© Copyright 2025. All Rights Reserved by MedPath